Filed by Zimmer Holdings, Inc.
                           Pursuant to Rule 425 under the Securities Act of 1933

                                                 Subject Company: Centerpulse AG
                                                   (Registration No. 333-105561)

                                           Subject Company: InCentive Capital AG
                                                   (Registration No. 333-105562)


On July 30, 2003, Zimmer Holdings, Inc. issued the following press release.




Contact:

                                   
        MEDIA                         INVESTORS
        Brad Bishop                   Sam Leno
        574/372-4291                  574/372-4790
        bradley.bishop@zimmer.com     sam.leno@zimmer.com




         ZIMMER ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS



(WARSAW, IN) JULY 30, 2003 - Zimmer Holdings, Inc. (NYSE: ZMH) announced today
that it has adjourned its special meeting of stockholders, which was reconvened
on July 30, 2003, to 11:00 a.m., Wednesday, August 6, 2003, at Zimmer's global
headquarters, 345 East Main Street, Warsaw, Indiana. The purpose of the special
meeting is to vote on the issuance of shares of Zimmer common stock in
connection with Zimmer's proposed acquisitions of Centerpulse AG and InCentive
Capital AG, a significant shareholder of Centerpulse. Approval of the issuance
requires the affirmative vote of holders of a majority of the shares of Zimmer
common stock present in person or by proxy at the special meeting and entitled
to vote thereon. At the time the special meeting was adjourned, Zimmer held
proxies for approximately 139 million shares, of which approximately 136
million shares (or 98%) were in favor of the issuance.


Zimmer believes that the additional time provided by this adjournment is
necessary to allow for the resolution of (i) appeals of Zimmer, Smith & Nephew
Group plc, Centerpulse AG and InCentive Capital AG pending before the Swiss
Federal Banking Commission relating to, among other things, the terms of
Zimmer's exchange offers and the timetable under which Zimmer's and Smith &
Nephew's exchange offers are proceeding and (ii) the uncertainty concerning the
final terms of Smith & Nephew's exchange offers.


SAFE HARBOR STATEMENT

This press release contains forward-looking statements based on current
expectations, estimates, forecasts and projections about the orthopaedics
industry, management's beliefs and assumptions made by management.
Forward-looking statements may be identified by the use of forward-looking terms
such as "may," "will," "expects," "believes," "anticipates," "plans,"
"estimates," "projects," "targets," "forecasts," and "seeks" or the negative of
such terms or other variations on such terms or comparable terminology. These
statements are not guarantees of future performance and involve risks,
uncertainties and assumptions that could cause actual outcomes and results to
differ materially. These risks and uncertainties include, but are not limited
to, price and product competition, rapid technological development, demographic
changes, dependence on new product development, the mix of our products and
services, supply and prices of raw materials and products, customer demand for
our products and services, our ability to successfully integrate acquired
companies, control of costs and expenses, our ability to form and implement
alliances, international growth, U.S. and foreign government regulation, product
liability and intellectual property litigation losses, reimbursement levels from
third-party payors, general industry and market conditions and growth rates and
general domestic and international economic conditions including interest rate
and currency exchange rate fluctuations. In particular, forward-looking
statements as to Zimmer's financial and business performance following the
proposed acquisitions should be qualified by the absence of the opportunity for
Zimmer to perform comprehensive due diligence on Centerpulse or InCentive
Capital AG, a significant shareholder of Centerpulse. These forward looking
statements might have been significantly different had such due diligence review
been undertaken. For a further list and description of such risks and
uncertainties, see the disclosure materials filed by Zimmer with the U.S.
Securities and Exchange Commission. Zimmer disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. Readers of this document are cautioned
not to place undue reliance on these forward-looking statements, since, while we
believe the assumptions on which the forward-looking statements are based are
reasonable, there can be no assurance that these forward-looking statements will
prove to be accurate. This cautionary statement is applicable to all
forward-looking statements contained in this document.

This press release is neither an offer to purchase nor a solicitation of an
offer to sell any securities. Any exchange offer will be made only through a
registration statement and related materials. Zimmer and its directors, officers
and other members of its management and employees also may be soliciting proxies
from Zimmer stockholders in connection with the exchange offers for shares of
Centerpulse and InCentive Capital AG. Investors and security holders should note
that the exchange offers described in this press release have not been agreed to
by Centerpulse or InCentive Capital AG and are subject to certain conditions. In
connection with the exchange offers, Zimmer has filed

registration statements on Form S-4 (each containing a prospectus/offer to
purchase) and a proxy statement on Schedule 14A with the U.S. Securities and
Exchange Commission and submitted Swiss offer prospectuses to the Swiss Takeover
Board. Investors and security holders of Centerpulse, InCentive Capital AG and
Zimmer are advised to read these disclosure materials (including other
disclosure materials when they become available), because these materials
contain important information. Investors and security holders may obtain a free
copy of the disclosure materials and other documents filed by Zimmer with the
U.S. Securities and Exchange Commission at the SEC's website at www.sec.gov. The
disclosure materials and other documents of Zimmer may also be obtained from
Zimmer upon request by directing such request to Sam Leno, Senior Vice President
and CFO, 574-372-4790.

ABOUT ZIMMER HOLDINGS, INC.

Zimmer, based in Warsaw, Indiana, is a worldwide leader in the design,
development, manufacture and marketing of reconstructive orthopaedic implants
and trauma products. Orthopaedic reconstruction implants restore joint function
lost due to disease or trauma in joints such as knees, hips, shoulders and
elbows. Trauma products are devices used primarily to reattach or stabilize
damaged bone and tissue to support the body's natural healing process. Zimmer
manufactures and markets other products related to orthopaedic surgery. For the
year 2002, the Company recorded worldwide revenues of $1.37 billion. Zimmer was
founded in 1927 and has more than 3,600 employees worldwide.

                                      # # #

Additional contacts:

         Switzerland: Hirzel. Neef. Schmid. Konsulenten
                      Aloys Hirzel/+41 43 344 42 49/a-hirzel@konsulenten.ch
                      Andreas Thommen/+41 43 344 42 49/
                      a-thommen@konsulenten.ch

         U.K.: M Communications
               Hugh Morrison/+44 207 153 1534/morrison@mcomgroup.com
               Nick Miles/+44 207 153 1535/miles@mcomgroup.com